NASDAQ:VSTM - Verastem Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.22 -0.19 (-3.51 %) (As of 11/19/2018 03:01 PM ET)Previous Close$5.41Today's Range$5.18 - $5.7152-Week Range$2.77 - $10.35Volume74,496 shsAverage Volume2.33 million shsMarket Capitalization$398.93 millionP/E Ratio-2.98Dividend YieldN/ABeta3.14 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Verastem, Inc., operating as a Verastem Oncology, is a biopharmaceutical company focuses on developing and commercializing medicines to improve the survival of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and is approved dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. The company is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, Verastem, Inc. is developing the focal adhesion kinase (FAK) inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Its product candidates seek to treat cancer by modulating the local tumor microenvironment and enhancing anti-tumor immunity. Verastem, Inc. has a collaboration agreement with The Leukemia & Lymphoma Society to develop duvelisib for the treatment of peripheral T-cell lymphoma. The company was founded in 2010 and is headquartered in Needham, Massachusetts. Receive VSTM News and Ratings via Email Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VSTM Previous Symbol CUSIP92337C10 Webwww.verastem.com Phone781-292-4200 Debt Debt-to-Equity Ratio0.20 Current Ratio2.97 Quick Ratio2.97 Price-To-Earnings Trailing P/E Ratio-2.98 Forward P/E Ratio-3.53 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.19 per share Price / Book4.39 Profitability EPS (Most Recent Fiscal Year)($1.76) Net Income$-67,800,000.00 Net MarginsN/A Return on Equity-95.94% Return on Assets-61.70% Miscellaneous Employees69 Outstanding Shares73,740,000Market Cap$398.93 million OptionableOptionable Verastem (NASDAQ:VSTM) Frequently Asked Questions What is Verastem's stock symbol? Verastem trades on the NASDAQ under the ticker symbol "VSTM." How were Verastem's earnings last quarter? Verastem Inc (NASDAQ:VSTM) announced its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.14. The biopharmaceutical company earned $15.51 million during the quarter. View Verastem's Earnings History. When is Verastem's next earnings date? Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Verastem. What price target have analysts set for VSTM? 9 equities research analysts have issued 12 month price targets for Verastem's stock. Their predictions range from $12.00 to $17.00. On average, they expect Verastem's stock price to reach $15.2222 in the next twelve months. This suggests a possible upside of 191.6% from the stock's current price. View Analyst Price Targets for Verastem. What is the consensus analysts' recommendation for Verastem? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem. What are Wall Street analysts saying about Verastem stock? Here are some recent quotes from research analysts about Verastem stock: 1. Cann analysts commented, "Verastem’s loss per share of $0.30 was in line with our estimated $0.30. There was an unanticipated upfront payment from Yakult of $10 million, in association with a collaboration agreement. This was offset by higher than estimated operating expense. SG&A of $15.8 million was higher than our estimated $90.0 million due to infrastructure ramp in association with the anticipated launch of Duvelisib in Q4 2018. R&D of $12.4 million exceeded our estimated $10.6 million due to further development of Duvelisib." (8/9/2018) 2. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (7/20/2018) 3. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018) 4. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018) Has Verastem been receiving favorable news coverage? News stories about VSTM stock have been trending somewhat positive on Monday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verastem earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. Are investors shorting Verastem? Verastem saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 18,654,118 shares, an increase of 13.1% from the October 15th total of 16,498,651 shares. Based on an average trading volume of 2,428,622 shares, the days-to-cover ratio is currently 7.7 days. Approximately 26.0% of the company's shares are sold short. View Verastem's Current Options Chain. Who are some of Verastem's key competitors? Some companies that are related to Verastem include Cambrex (CBM), Enanta Pharmaceuticals (ENTA), G1 Therapeutics (GTHX), Corcept Therapeutics (CORT), The Medicines (MDCO), Theravance Biopharma (TBPH), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Insmed (INSM), Mirati Therapeutics (MRTX), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA) and Tricida (TCDA). Who are Verastem's key executives? Verastem's management team includes the folowing people: Mr. Robert Forrester, Pres, CEO & Director (Age 54)Dr. NgocDiep T Le M.D., Ph.D., Chief Medical Officer (Age 50)Mr. Richard H. Aldrich, Founder and Consultant (Age 64)Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory BoardDr. Piyush B. Gupta, Co-Founder Who are Verastem's major shareholders? Verastem's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.31%), FMR LLC (4.51%), Man Group plc (1.01%), Teachers Advisors LLC (0.65%), Allianz Asset Management GmbH (0.42%) and Fuller & Thaler Asset Management Inc. (0.35%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem. Which institutional investors are selling Verastem stock? VSTM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Bank of New York Mellon Corp, Bridgeway Capital Management Inc., Virtus ETF Advisers LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Verastem. Which institutional investors are buying Verastem stock? VSTM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Man Group plc, Teachers Advisors LLC, Fuller & Thaler Asset Management Inc., Cohen Capital Management Inc., Jane Street Group LLC, Dynamic Technology Lab Private Ltd and Allianz Asset Management GmbH. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Insider Buying and Selling for Verastem. How do I buy shares of Verastem? Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Verastem's stock price today? One share of VSTM stock can currently be purchased for approximately $5.22. How big of a company is Verastem? Verastem has a market capitalization of $398.93 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe. What is Verastem's official website? The official website for Verastem is http://www.verastem.com. How can I contact Verastem? Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected] MarketBeat Community Rating for Verastem (NASDAQ VSTM)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 363 (Vote Outperform)Underperform Votes: 235 (Vote Underperform)Total Votes: 598MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: What factors cause inflation to rise?